Cell No. : Cell Name RCB5977 : HCT116 CERT1 KO  update : 2024/07/18
Comment			Currently not ready.
Comment from the depositor			A mutant cell line was developed in the human colon carcinoma-derived HCT 116 cell line, in which the CERT1 gene encoding the ceramide transport protein was disrupted using the CRISPR/Cas9 technology.
Terms and conditions
Remarks
Order Form
			Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
	Basic information	Expected time	Upon a request we will start preparation. Contact us: cellkitaku.brc@riken.jp
		IPR	National Institute of Infectious Diseases (Japan)
		Depositor	HANADA, Kentaro
Reference information		Reference	2
		User's Publication	0

Top

Reference

21780  Tamura N, Sakai S, Martorell L, Colomé R, Mizuike A, Goto A, Ortigoza-Escobar JD, Hanada K.  Intellectual disability-associated mutations in the ceramide transport protein gene CERT1 lead to aberrant function and subcellular distribution.  J Biol Chem  2021  101338  PubMed ID: 34688657   DOI: 10.1016/j.jbc.2021.101338

21779  Murakami H, Tamura N, Enomoto Y, Shimasaki K, Kurosawa K, Hanada K.  Intellectual disability-associated gain-of-function mutations in CERT1 that encodes the ceramide transport protein CERT.  PLoS One  2020  15(12):e0243980  PubMed ID: 33347465   DOI: 10.1371/journal.pone.0243980

Top

User's Publication